MedTrace Logo

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

NCT01852214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-17

Study results available
· View outcomes & findings →

Summary

Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular the P2Y12 receptor inhibitor clopidogrel, used for secondary prevention of ischemic events. Prasugrel and ticagrelor are recently approved P2Y12 receptor inhibitors which, compared with clopidogrel, have more potent antiplatelet effects. Head-to-head comparisons between the two drugs are lacking.

Conditions

Interventions

DRUG

Prasugrel

Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose

DRUG

Ticagrelor

Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Dominick Angiolillo, MD, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01852214 on ClinicalTrials.gov